Joined the BIE Board as a Non-Executive Director in 2025 

Laura Parton is the Vice President of R&D Project & Portfolio Strategy at Charm Therapeutics, where she leads project portfolio management to drive preclinical and clinical drug development for next-generation oncology therapies. With 20 years of experience spanning academia and the pharma/biotech industry, she has successfully advanced first-in-class clinical candidates from early discovery through to early-stage clinical trials in kidney disease and Parkinson’s disease.

Laura brings expertise in translating early-stage research into viable clinical candidates, strategically balancing scientific innovation with financial and operational considerations to optimise project success. Her background spans basic research, clinical development, and commercial strategy, enabling her to shape project strategies that maximise both scientific and commercial value.

Before joining Charm Therapeutics, Laura held scientific and cross-functional programme management roles at Mission Therapeutics, Takeda, and Abcam. She holds a BSc in Biochemistry from the University of Manchester, a PhD from the University of Bristol, and completed postdoctoral research at Harvard Medical School.